FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800620132> ?p ?o ?g. }

• W2800620132 endingPage "1488" @default.
• W2800620132 startingPage "1486" @default.
• W2800620132 abstract "Dear Editor, In the combined anti-retroviral therapy (cART) era, non-small-cell lung cancer (NSCLC) is a highly incident cause of morbidity and mortality in people living with HIV (PLHIV) [1.Bower M. Powles T. Nelson M. et al.HIV-related lung cancer in the era of highly active antiretroviral therapy.AIDS. 2003; 17: 371-375Crossref PubMed Scopus (131) Google Scholar]. The immune-pathogenesis of NSCLC and HIV infection both rely on programmed-death 1 (PD-1) receptor–ligand interaction as a mechanism to induce T-cell exhaustion. To date, PLHIV have been excluded from clinical trials of immune-checkpoint inhibitors (ICPI), on the presumption that antitumour immunity might be compromised by HIV infection. To verify this, we evaluated the clinico-pathological significance of PD-ligands expression in a consecutive series of 221 archival NSCLC samples, 24 of which were HIV-associated (supplementary Table S1, available at Annals of Oncology online). Most patients with HIV-associated NSCLC were active smokers (n = 18, 75%; median 40 packs/year, IQR 48), established on cART (n = 22, 92%) for a median duration of 9.7 years (IQR 7.1) with CD4 counts >250 cells/mm3 (n = 19, 79%) and suppressed HIV RNA (n = 20, 80%). Molecular profiling data (n = 12/24) revealed two EGFR mutation carriers. Tissue-microarray sections underwent PD-L1, PD-L2 immunostaining and multiplex immunohistochemistry (n = 21) for PD-1, CD4, CD8 and CD68 (Figure 1A–D, supplementary materials, available at Annals of Oncology online). Prevalence of PD-L1 positivity was 45% in tumour (n = 11/24) and 8% (n = 2/24) in tumour-infiltrating cells, whereas tumoural PD-L2 positivity was found in 33% (n = 8/24) (supplementary Figures S1, available at Annals of Oncology online). Following 2 : 1 case–control matching for age, gender, grade, stage and histotype (n = 66), PD-L1 (12/23 versus14/43, P = 0.12) and PD-L2 expression (9/23 versus 25/45, P = 0.20) were unrelated to the presence and severity of HIV-related immune dysfunction as indicated by nadir CD4 counts (P = 1.0, P = 0.8), HIV RNA levels (P = 0.14, P = 0.24), duration of HIV infection and cART (P > 0.05) suggesting independence between antiviral and antitumour immune-tolerogenesis. In keeping with this view, we documented a positive correlation between PD-L1 expression and density of tumour-infiltrating (TIL) (Figure 1A–F) but not peripherally circulating lymphocytes (Figure 1G and H), highlighting polarization of the tumour microenvironment to a type-1 response [2.Teng M.W. Ngiow S.F. Ribas A. Smyth M.J. Classifying cancers based on T-cell infiltration and PD-L1.Cancer Res. 2015; 75: 2139-2145Crossref PubMed Scopus (977) Google Scholar]. In type-1 or PD-L1+/TIL+ tumours, TILs are chemo-attracted to malignant cells and turned off by PD-L1 engagement. Type-1 tumours are generally sensitive to single-agent PD-1/PD-L1-targeted checkpoint blockade, due to the presence of an immune-reactive microenvironment [3.Taube J.M. Klein A. Brahmer J.R. et al.Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res. 2014; 20: 5064-5074Crossref PubMed Scopus (1816) Google Scholar]. In an exploratory targeted transcriptomic analysis of five HIV-positive cases and three stage/histotype-matched controls using the NanoString PanCancer-Immune panel (NanoString Technologies, Seattle), we demonstrated enrichment of transcripts involved in chemotaxis (CCL18), antigen presentation (HLA-A, HLA-DRA), cytotoxic T-cell (LAMP-1) and macrophage activation (SPP1, Figure 1I and J) in HIV-associated NSCLC, consistent with previous studies [4.Domblides C. Antoine M. Hamard C. et al.Non-small cell lung cancer from HIV-infected patients expressed PD-L1 with marked inflammatory infiltrates.AIDS. 2017; : 1Crossref PubMed Scopus (13) Google Scholar]. Whilst not exhaustive and limited by sample size, our findings challenge the conception that well-controlled HIV infection may negatively influence cancer-specific immune dysfunction by preliminarily demonstrating the presence of an immune-reactive microenvironment in HIV-associated NSCLC (supplementary Figures S2, S3, Tables S2 and S3, available at Annals of Oncology online). This concept should be further explored by comparing normal and neoplastic lung tissues in prospective studies. As accumulating evidence shows PD-1/PD-L1-targeted ICPI to be safe and capable of enhancing HIV-specific immunity [5.Guihot A. Marcelin A.G. Massiani M.A. et al.Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.Ann Oncol. 2018; 29: 517-518Abstract Full Text Full Text PDF PubMed Scopus (116) Google Scholar] without unexpected toxicity, taken together, our data suggest that HIV-associated NSCLC may be equally reactive to ICPI. Whilst preliminary in nature and warranting validation in larger patient cohorts treated with ICPI, our study supports an immunobiological rationale for the development of PD-1/PD-L1-targeted ICPI in HIV-associated NSCLC. The authors would like to acknowledge the Imperial College Healthcare NHS Trust Tissue Bank for having supported the study. DJP is supported by grant funding from the National Institute for Health Research (NIHR), the Imperial Biomedical Research Centre and the Academy of Medical Sciences (AMS Grant ID SGL013/1021). The AMS Starter Grant is jointly funded by the AMS, Wellcome Trust, Medical Research Council, British Heart Foundation, Arthritis Research UK, the Royal College of Physicians and Diabetes UK." @default.
• W2800620132 created "2018-05-17" @default.
• W2800620132 creator A5001343667 @default.
• W2800620132 creator A5001737873 @default.
• W2800620132 creator A5004783631 @default.
• W2800620132 creator A5009625482 @default.
• W2800620132 creator A5015906510 @default.
• W2800620132 creator A5020822922 @default.
• W2800620132 creator A5029185427 @default.
• W2800620132 creator A5032333119 @default.
• W2800620132 creator A5039485950 @default.
• W2800620132 creator A5040185853 @default.
• W2800620132 creator A5041522709 @default.
• W2800620132 creator A5063608129 @default.
• W2800620132 creator A5063643387 @default.
• W2800620132 creator A5087205758 @default.
• W2800620132 date "2018-06-01" @default.
• W2800620132 modified "2023-10-12" @default.
• W2800620132 title "Functional immune characterization of HIV-associated non-small-cell lung cancer" @default.
• W2800620132 cites W1889335134 @default.
• W2800620132 cites W2072437203 @default.
• W2800620132 cites W2109485845 @default.
• W2800620132 cites W2774734531 @default.
• W2800620132 doi "https://doi.org/10.1093/annonc/mdy125" @default.
• W2800620132 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6005048" @default.
• W2800620132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29897389" @default.
• W2800620132 hasPublicationYear "2018" @default.
• W2800620132 type Work @default.
• W2800620132 sameAs 2800620132 @default.
• W2800620132 citedByCount "11" @default.
• W2800620132 countsByYear W28006201322018 @default.
• W2800620132 countsByYear W28006201322020 @default.
• W2800620132 countsByYear W28006201322021 @default.
• W2800620132 countsByYear W28006201322022 @default.
• W2800620132 countsByYear W28006201322023 @default.
• W2800620132 crossrefType "journal-article" @default.
• W2800620132 hasAuthorship W2800620132A5001343667 @default.
• W2800620132 hasAuthorship W2800620132A5001737873 @default.
• W2800620132 hasAuthorship W2800620132A5004783631 @default.
• W2800620132 hasAuthorship W2800620132A5009625482 @default.
• W2800620132 hasAuthorship W2800620132A5015906510 @default.
• W2800620132 hasAuthorship W2800620132A5020822922 @default.
• W2800620132 hasAuthorship W2800620132A5029185427 @default.
• W2800620132 hasAuthorship W2800620132A5032333119 @default.
• W2800620132 hasAuthorship W2800620132A5039485950 @default.
• W2800620132 hasAuthorship W2800620132A5040185853 @default.
• W2800620132 hasAuthorship W2800620132A5041522709 @default.
• W2800620132 hasAuthorship W2800620132A5063608129 @default.
• W2800620132 hasAuthorship W2800620132A5063643387 @default.
• W2800620132 hasAuthorship W2800620132A5087205758 @default.
• W2800620132 hasBestOaLocation W28006201322 @default.
• W2800620132 hasConcept C121608353 @default.
• W2800620132 hasConcept C126322002 @default.
• W2800620132 hasConcept C143998085 @default.
• W2800620132 hasConcept C203014093 @default.
• W2800620132 hasConcept C2776256026 @default.
• W2800620132 hasConcept C71924100 @default.
• W2800620132 hasConceptScore W2800620132C121608353 @default.
• W2800620132 hasConceptScore W2800620132C126322002 @default.
• W2800620132 hasConceptScore W2800620132C143998085 @default.
• W2800620132 hasConceptScore W2800620132C203014093 @default.
• W2800620132 hasConceptScore W2800620132C2776256026 @default.
• W2800620132 hasConceptScore W2800620132C71924100 @default.
• W2800620132 hasFunder F4320307874 @default.
• W2800620132 hasFunder F4320308427 @default.
• W2800620132 hasFunder F4320319990 @default.
• W2800620132 hasFunder F4320319992 @default.
• W2800620132 hasFunder F4320320045 @default.
• W2800620132 hasFunder F4320320241 @default.
• W2800620132 hasFunder F4320334626 @default.
• W2800620132 hasIssue "6" @default.
• W2800620132 hasLocation W28006201321 @default.
• W2800620132 hasLocation W28006201322 @default.
• W2800620132 hasLocation W28006201323 @default.
• W2800620132 hasLocation W28006201324 @default.
• W2800620132 hasLocation W28006201325 @default.
• W2800620132 hasOpenAccess W2800620132 @default.
• W2800620132 hasPrimaryLocation W28006201321 @default.
• W2800620132 hasRelatedWork W1966504330 @default.
• W2800620132 hasRelatedWork W1974041167 @default.
• W2800620132 hasRelatedWork W1979139803 @default.
• W2800620132 hasRelatedWork W2030889776 @default.
• W2800620132 hasRelatedWork W2037631372 @default.
• W2800620132 hasRelatedWork W2040058909 @default.
• W2800620132 hasRelatedWork W2070567609 @default.
• W2800620132 hasRelatedWork W2073527559 @default.
• W2800620132 hasRelatedWork W2159000141 @default.
• W2800620132 hasRelatedWork W2391409986 @default.
• W2800620132 hasVolume "29" @default.
• W2800620132 isParatext "false" @default.
• W2800620132 isRetracted "false" @default.
• W2800620132 magId "2800620132" @default.
• W2800620132 workType "article" @default.